Post-earnings recap
Reported
Thu, Nov 7, 2024
EPS actual
$-0.36
EPS est.
$-0.37
EPS surprise
+3.74%
1-day move
-3.25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edgewise Therapeutics reported a narrower-than-expected loss per share but did not provide revenue figures. The stock fell 3.25% likely due to the lack of revenue information and no guidance for future performance. Investors may be concerned about the company's ability to generate revenue in the near term, given the absence of specific updates.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | +3.74% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding their future projects and collaborations. They emphasized the importance of their ongoing research efforts.
Management highlighted ongoing efforts in drug development and partnerships.
They expressed confidence in the long-term potential of their pipeline.